Filing Flows

Filing Flows › Companies › Arbutus Biopharma › Cash flow

Arbutus Biopharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.0M in Q2 2026 · −$24.6M over twelve months

Operating cash flow−$6.0M
Free cash flow−$6.0M

Analysis

In Q2 2026, Arbutus Biopharma generated −$6.0M of operating cash flow. That is $9.7M more than in Q2 2025 (−$15.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$24.6M; the largest uses were operating cash flow ($24.6M), other investing ($11.2M); besides operations, cash came from shares issued ($17.1M), asset & business sales ($355K); the cash balance fell by $18.2M.

Operating cash flow was −$6.0M against net income of −$5.1M. The largest differences: stock-based pay +$1.6M, payables −$1.6M, prepaid and other assets +$215K.

Free cash flow

Arbutus Biopharma: free cash flow by quarterArbutus Biopharma: free cash flow by quarter−$20.7MQ3 2024−$10.4MQ4 2024−$13.4MQ1 2025−$15.7MQ2 2025−$5.8MQ3 2025−$4.7MQ4 2025−$8.1MQ1 2026−$6.0MQ2 2026
Operating cash flow less capital spending.
Arbutus Biopharma: operating cash flow against capital spendingArbutus Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$20.7M$0Q3 2024−$10.3M$86KQ4 2024−$13.4M$0Q1 2025−$15.7M$0Q2 2025−$5.8M$0Q3 2025−$4.7M$0Q4 2025−$8.1M$0Q1 2026−$6.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$6.0M, Capital spending $0.

Capital allocation, year by year

Arbutus Biopharma: where the cash came from (up) and went (down), by fiscal yearArbutus Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$67.5MFY2021: Shares issued $137MFY2021: Capital spending −$809K$137MFY2021FY2022: Operating cash flow −$35.4MFY2022: Shares issued $122KFY2022: Capital spending −$512K$122KFY2022FY2023: Operating cash flow −$85.9MFY2023: Shares issued $260KFY2023: Asset sales $20KFY2023: Capital spending −$1.0M$280KFY2023FY2024: Operating cash flow −$64.8MFY2024: Shares issued $7.5MFY2024: Capital spending −$182K$7.5MFY2024FY2025: Operating cash flow −$39.6MFY2025: Shares issued $5.5MFY2025: Asset sales $364K$5.9MFY2025
Over these 5 years operating cash flow totalled −$293M; the largest uses were operating cash flow ($293M) and capital spending ($2.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$92.6M
Debtnone
Net cash$92.6M
Cash runway3.8 years

Arbutus Biopharma is burning cash: its operations consume cash, a free cash flow of −$24.6M a year at the current rate against $92.6M of cash and investments: a runway of about 3.8 years before any new financing.

Where the cash came from and went

Arbutus Biopharma: sources (+) and uses (−) of cash, Q2 2026Arbutus Biopharma: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$6.0MCash drawn (+) / kept (−)$4.5MShares issued$3.1MOther investing−$1.7MExchange rates−$4K
Arbutus Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Arbutus Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$24.6MCash drawn (+) / kept (−)$18.2MShares issued$17.1MOther investing−$11.2MAsset & business sales$355KOther financing$138KExchange rates−$25K

From profit to cash

Arbutus Biopharma: net income to operating cash flow, Q2 2026Arbutus Biopharma: net income to operating cash flow, Q2 2026Net income−$5.1MDepreciation & amortization$11KStock-based pay$1.6MReceivables−$82KPayables−$1.6MPrepaid and other assets$215KOther liabilities−$113KOperating cash flow−$6.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.0M—$3.1M$4.5M−$6.0M
Q1 2026−$8.1M—$11.5M−$5.7M−$8.1M
Q4 2025−$4.7M—$1.6M$4.4M−$4.7M
Q3 2025−$5.8M—$794K$15.0M−$5.8M
Q2 2025−$15.7M—$453K−$336K−$15.7M
Q1 2025−$13.4M—$2.7M−$746K−$13.4M
Q4 2024−$10.3M−$86K$1.4M−$4.5M−$10.4M
Q3 2024−$20.7M—$1.6M$30.9M−$20.7M

Arbutus Biopharma: income statement and cash flow

Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%. The chart follows the revenue to costs, profit and cash.

Arbutus Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.